Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Richard M. Schraeder

Hematology Oncology | Hematology | Oncology
University Of Maryland St Joseph Medical Group LLC
7601 Osler Dr, 
Towson, MD 
Accepting New Patients
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
University Of Maryland St Joseph Medical Group LLC
7601 Osler Dr, 
Towson, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Hahneman Medical College Of The Pacific
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
University Of Maryland Medical Center
Wellspan York Hospital
University Of MD St Joseph Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY OF MARYLAND ST JOSEPH MEDICAL GROUP LLC
7601 Osler Dr, Towson, MD 21204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

The changing pathology of lung cancer.
The changing pathology of lung cancer.
Journal: Surgical oncology clinics of North America
Published: October 12, 2011
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Jamal G. Misleh
Hematology Oncology | Hematology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Jamal G. Misleh
Hematology Oncology | Hematology | Oncology

Medical Oncology Hematology Consultants PA

4701 Ogletown Stanton Rd, Suite 3400, 
Newark, DE 
 (54.0 miles away)
302-366-1200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jamal Misleh is a Hematologist Oncology specialist and a Hematologist in Newark, Delaware. Dr. Misleh is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Neuroendocrine Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Misleh is currently accepting new patients.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Robert J. Christie
Hematology Oncology | Hematology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Robert J. Christie
Hematology Oncology | Hematology | Oncology

Virginia Cancer Specialists, P.C.

1635 N George Mason Dr, Suite 170, 
Arlington, VA 
 (44.3 miles away)
703-894-3800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Christie is a Hematologist Oncology specialist and a Hematologist in Arlington, Virginia. Dr. Christie is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Multiple Myeloma. Dr. Christie is currently accepting new patients.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Ramya Varadarajan
Hematology Oncology | Hematology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Ramya Varadarajan
Hematology Oncology | Hematology | Oncology

Christiana Care Health Services Inc

4701 Ogletown Stanton Rd, 
Newark, DE 
 (54.0 miles away)
302-623-3605
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Ramya Varadarajan is a Hematologist Oncology specialist and a Hematologist in Newark, Delaware. Dr. Varadarajan is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Inflammatory Breast Cancer. Dr. Varadarajan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schraeder's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile